Page 34 - TD-2-3

Tumor Discovery Targeted drug delivery systems for the treatment of tumors

119. Zheng N, Gao Y, Ji H, et al., 2016, Vitamin E derivative-based 129. Seleci DA, Seleci M, Walter JG, et al., 2016, Niosomes
multifunctional nanoemulsions for overcoming multidrug as nanoparticular drug carriers. J Nanomaterials,
resistance in cancer. J Drug Target, 24: 663–669. 2016: 7372306.
https://doi.org/10.3109/1061186X.2015.1135335 130. Ruoslahti E, 2012, Peptides as targeting elements and
tissue penetration devices for nanoparticles. Adv Mater, 24:
120. Ahmad G, El-Sadda R, Botchkina G, et al., 2017, 3747–3756.
Nanoemulsion formulation of a novel taxoid DHA-
SBT-1214 inhibits prostate cancer stem cell-induced tumor https://doi.org/10.1002/adma.201200454
growth. Cancer Lett, 406: 71–80.
131. Dahir L, Kajol Kaur A, Manocha A, et al., 2020, Aquasomes:
https://doi.org/10.1016/j.canlet.2017.08.004 Water like bodies vesicular system for therapeutics molecules
as robust system for delivery. EJMCM, 7: 2585–2607.
121. Bozzuto G, Molinari A, 2015, Liposomes as nanomedical
devices. Int J Nanomedicine, 10: 975–999. 132. Gaikwad SS, Morade YY, Kothule AM, et al., 2023, Overview
of phytosomes in treating cancer: Advancement, challenges,
https://doi.org/10.2147/IJN.S68861
and future outlook. Heliyon, 9: e16561.
122. Gonda A, Zhao N, Shah J, et al., 2019, Engineering https://doi.org/10.1016/j.heliyon.2023.e16561
tumor-targeting nanoparticles as vehicles for precision
nanomedicine. Med One, 4: e190021. 133. Azeez NA, Deepa VS, Sivapriya V, 2018, Phytosomes:
Emergent promising nano vesicular drug delivery system for
https://doi.org/10.20900/mo.20190021 targeted tumor therapy. Adv Nat Sci Nanosci Nanotechnol,
123. Eloy JO, Petrilli R, Chesca DL, et al., 2017, Anti-HER2 9: 033001.
immunoliposomes for co-delivery of paclitaxel and 134. Dancey JE, 2005, Inhibitors of the mammalian target of
rapamycin for breast cancer therapy. Eur J Pharm Biopharm, rapamycin. Expert Opin Investig Drugs, 14: 313–328.
115: 159–167.
https://doi.org/10.1517/13543784.14.3.313
https://doi.org/10.1016/j.ejpb.2017.02.020
135. Stark FC, Weeratna RD, Deschatelets L, et al., 2017, An
124. Prasad R, Jain NK, Yadav AS, et al., 2020, Liposomal archaeosome-adjuvanted vaccine and checkpoint inhibitor
nanotheranostics for multimode targeted in vivo bioimaging therapy combination significantly enhances protection from
and near-infrared light mediated cancer therapy. Commun murine melanoma. Vaccines (Basel), 5: 38.
Biol, 3: 284.
https://doi.org/10.3390/vaccines5040038
https://doi.org/10.1038/s42003-020-1016-z
136. Lee YK, Lee TS, Song IH, et al., 2015, Inhibition of
125. Yin W, Zhao Y, Kang X, et al., 2020, BBB-penetrating pulmonary cancer progression by epidermal growth factor
codelivery liposomes treat brain metastasis of non-small receptor-targeted transfection with Bcl-2 and survivin
cell lung cancer with EGFR T790M mutation. Theranostics, siRNAs. Cancer Gene Ther, 22: 335–343.
10: 6122–6135.
https://doi.org/10.1038/cgt.2015.18
https://doi.org/10.7150/thno.42234
137. Yang Y, Yang Y, Xie X, et al., 2016, Dual stimulus of
126. Gharbavi M, Amani J, Kheiri-Manjili H, et al., 2018, hyperthermia and intracellular redox environment triggered
Niosome: A promising nanocarrier for natural drug release of siRNA for tumor-specific therapy. Int J Pharm,
delivery through blood-brain barrier. Adv Pharmacol Sci, 506: 158–173.
2018: 6847971.
https://doi.org/10.1016/j.ijpharm.2016.04.035
127. Mohamad Saimi NI, Salim N, Ahmad N, et al., 2021,
Aerosolized niosome formulation containing gemcitabine 138. Karpuz M, Silindir-Gunay M, Ozer AY, et al., 2021,
and cisplatin for lung cancer treatment: Optimization, Diagnostic and therapeutic evaluation of folate-targeted
characterization and in vitro evaluation. Pharmaceutics, paclitaxel and vinorelbine encapsulating theranostic
13: 59. liposomes for non-small cell lung cancer. Eur J Pharm Sci,
56: 105576.
https://doi.org/10.3390/pharmaceutics13010059
https://doi.org/10.1016/j.ejps.2020.105576
128. Kulkarni P, Rawtani D, 2019, Application of box-
behnken design in the preparation, optimization, and in 139. Tavano L, Mauro L, Naimo GD, et al., 2016, Further
vitro evaluation of self-assembly-based tamoxifen- and evolution of multifunctional niosomes based on pluronic
doxorubicin-loaded and dual drug-loaded niosomes surfactant: Dual active targeting and drug combination
for combinatorial breast cancer treatment. J Pharm Sci, properties. Langmuir, 32: 8926–8933.
108: 2643–2653. https://doi.org/10.1021/acs.langmuir.6b02063
https://doi.org/10.1016/j.xphs.2019.03.020 140. Khan DH, Bashir S, Correia A, et al., 2019, Utilization of

Volume 2 Issue 3 (2023) 28 https://doi.org/10.36922/td.1356